Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for preventing medicine-related osteonecrosis of jaw

A technology for preventing drugs and drugs, applied in drug combinations, bone diseases, pharmaceutical formulations, etc., and can solve problems such as unseen TFNAs

Pending Publication Date: 2020-07-31
SICHUAN UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report about TFNAs used as active ingredients of drugs to prevent drug-induced osteonecrosis of the jaw

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for preventing medicine-related osteonecrosis of jaw
  • Medicine for preventing medicine-related osteonecrosis of jaw
  • Medicine for preventing medicine-related osteonecrosis of jaw

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation and verification of embodiment 1 complex of the present invention

[0032] 1. Preparation of TFNAs

[0033] Dissolve the four DNA single strands (S1, S2, S3, S4) in TM Buffer (10mM Tris-HCl, 50mM MgCl2, pH=8.0), the final concentration of the four DNA single strands is 1000nM, mix well, and rapidly heat to 95 ℃ for 10 minutes, and then rapidly cooled to 4 ℃ and maintained for more than 20 minutes to obtain TFNAs. Synthesis schematic as figure 1 As shown in A.

[0034] When fluorescent labeling is required, a fluorescent group, such as Cy5, can be attached to the 5' end of any DNA single strand.

[0035] The sequences of the four single strands (5'→3') are as follows:

[0036]

[0037] 2. Identification

[0038] DNA tetrahedron after synthesis, the result of PAGE glue shows that the size of DNA tetrahedron is about 180bp, it can be considered that DNA tetrahedron has been successfully synthesized ( figure 1 C). The results of dynamic light scatt...

experiment example 1

[0040] Experimental example 1 In vitro model experiment

[0041] 1. Method

[0042] 1.1 Construction of BRONJ in vitro model

[0043] RAW264.7 cells (a kind of mononuclear macrophage) in logarithmic growth phase were collected and divided into Control group, ZA (zoledronic acid) group, and TFNAs+ZA group. When the cells adhered to the wall for 24 hours, the treatment conditions of the three groups were as follows: a) Control group: 5% serum medium, 50ng / ml RANKL (activator of nuclear factor kappa B receptor ligand, also known as "osteoclast differentiation factor") supply; b) ZA group: medium containing 5% serum, while adding 10μM ZA and 50ng / ml RANKL; c) medium containing 5% serum, adding 50ng / ml RANKL, 10μM ZA and 250nM TFNAs, for 120h ( Medium was changed every 2 days).

[0044] In this experimental example, the role of RANKL is to promote the differentiation of RAW 264.7 cells into osteoclasts.

[0045] 1.2 CCK8 cytotoxicity test

[0046] RAW264.7 cells were cultured ...

experiment example 2

[0079] Experimental Example 2 Animal experiment

[0080] 1. Method

[0081] Thirty 8-week-old Wistar male rats weighing 180-200 g were randomly divided into three groups: control group, ZA group and TFNAs+ZA group. Each rat was intraperitoneally injected with dexamethasone (5 mg / kg) for 5 weeks. Animals in the ZA group and the TFNAs+ZA group received intraperitoneal injections of ZA (125 μg / kg) twice a week for 5 weeks. The TFNAs+ZA group received daily intraperitoneal injection of TFNAs within 1 week after tooth extraction. The control group was treated with the same dose of normal saline for 5 weeks. Tooth extraction was performed in the second week of the animal experiment, that is, one week after intraperitoneal injection of dexamethasone and ZA. The gums around the molars are separated by a dental explorer. Using a vascular forceps as a forceps, excise the left maxillary first molar. Stop the bleeding by pressing on the extraction socket with a cotton ball.

[0082...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for preventing medicine-related osteonecrosis of the jaw. The medicine uses a DNA tetrahedron as an effective ingredient. Experiments show that the DNA tetrahedron can reverse the inhibitory effect of zoledronic acid, dexamethasone and other medicines on osteoclast, and can relatively well prevent medicine-related osteonecrosis of the jaw.

Description

technical field [0001] The invention relates to a medicine for preventing drug-induced osteonecrosis of the jaw. Background technique [0002] Bisphosphonates (bisphosphonates, BPs) are a new class of drugs for various bone diseases and calcium metabolism diseases. It can specifically combine with hydroxyphospholime in bone, inhibit the activity of osteoclasts, and thereby inhibit bone resorption. For the treatment of osteoporosis, osteitis deformans, hypercalcemia and bone pain caused by malignant tumor bone metastasis. [0003] In recent years, more and more reports have shown that the use of BPs may lead to drug-induced osteonecrosis of the jaw (MRONJ), which is the main cause of MRONJ. The disease is clinically characterized by exposed bone surfaces, sequestrum formation, pain, and bad breath. Due to the unclear pathogenesis of MRONJ, there is no completely effective treatment in clinical practice. [0004] DNA tetrahedral framework nucleic acids (TFNAs) are tetrahed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/711A61P19/08
CPCA61K31/711A61P19/08
Inventor 林云锋崔伟同
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com